Sangamo today announced results for its 2Q of 2011.  The low revenue indicates that royalties from the 2 ZFP partner programs has still not accelerated.  However, the most important aspect of the release was the confirmation of upcoming clinical milestones:

 

In the second half of 2011, the company expects the following clinical data milestones in its two lead ZFP Therapeutic® programs:  

 

• Announcement of clinical trial results from Sangamo's double-blind, placebo-controlled Phase 2b trial (SB-509-901) of SB-509 for the treatment of moderately severe diabetic neuropathy in the fourth quarter of 2011.
• Presentation of additional data from its SB-728-T clinical trials. Data from all dosing cohorts of the SB-728-902 study in aviremic subjects will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which will be held September 17- 20, 2011, in Chicago.

 

During the call, they reiterated revenue and earnings guidance for the year.   Royalties and revenue will be backend loaded into the 2nd half of the year and specifically in the fourth quarter where DOW minimum royalties are paid.  

 

During the 3rd and 4th quarter, we now have 3 data events:  The ICAAC presentation in September, the SB-509 data release in Q4, and the SB-728-T 1002 study in viremic patients.  With only a month and half until the beginning of the data releases and 3 investor presentations scheduled for September-- the 2nd half of the year will provide a lot of updates for investors.

 

The CEO reiterated on the call that 2011 is a transformational year for Sangamo.